课题基金 / 基金详情

PHASE II REPETITIVE IV DOSES OF RSR13 TO PT RECEIVING CRANIAL RADIATI

PHASE II REPETITIVE IV DOSES OF RSR13 TO PT RECEIVING CRANIAL RADIATI
对接受颅脑放射治疗的 PT 进行第二阶段 RSR13 重复 IV 剂量
批准号：
6309872
负责人：
GLENN J LESSER
金额：
$2.42万
依托单位：
WAKE FOREST UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2001-02-28
来源：
https://reporter.nih.gov/project-details/6309872
关键词：
astrocytoma clinical research cytotoxicity drug administration rate /duration drug adverse effect drug screening /evaluation glioblastoma multiforme human subject human therapy evaluation injection /infusion intravenous administration longitudinal human study neoplasm /cancer chemotherapy neoplasm /cancer radiation therapy neoplastic process pharmacokinetics propionates sickling inhibitor

项目摘要

项目成果

GLENN J LESSER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study is to determine the efficacy, safety, pharmacokinetics and pharmacodynamics of multiple daily IV infusions of RSR13 at a therapeutically relevant daily dose (100 mg/kg) administered immediately prior to radiation therapy in patients with glioblastoma multiforme. This tumor is almost never cured with surgery, radiation therapy or chemotherapy. This research study is designed to look for evidence that RSR13 may improve results of radiation therapy for treatment of this type of tumor and to evaluate the safety and tolerance of RSR13 when given with radiation therapy. RSR13 is an investigational drug that increases the amount of oxygen released from the blood into the tissues. Lack of oxygen in a tumor can reduce the effectiveness of radiation therapy, therefore, RSR13 may improve the effectiveness of radiation therapy by increasing oxygen delivery to the tumor.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Wake Forest NCORP Research Base
Wake Forest NCORP Research Base
Wake Forest NCORP Research Base
Wake Forest NCORP Research Base
海外基金